2024 年 6 月 5-7 日在西班牙巴塞罗那举行的第 58 届欧洲科学理事会年度科学会议。

IF 4.4 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
{"title":"2024 年 6 月 5-7 日在西班牙巴塞罗那举行的第 58 届欧洲科学理事会年度科学会议。","authors":"","doi":"10.1111/eci.14236","DOIUrl":null,"url":null,"abstract":"<p>Welcome to Barcelona.</p><p>On behalf of the Organizing Committee, it is a pleasure to invite you to the</p><p><b>58th Annual Scientific Meeting</b> of the <b>European Society of Clinical Investigation</b>, which will be held in the lively city of <b>Barcelona</b>, Spain, <b>June 5-7, 2024</b></p><p>Both the whole Council of ESCI and the Local Organisers are committed to offering you a unique scientific event to stay at the forefront of the newest scientific discoveries, connect with peers, and contribute to the collective advancement of medical practice through science.</p><p>The <b>Congress Programme</b>, embraced under the theme <b>\"Connecting the Dots: The Power of Integrative Medicine</b>\", will feature eight different Symposiums running in parallel to provide a holistic and multidisciplinary overview of human health and disease. The symposium will cover: S1) the pathology and physiology of mitochondria; S2) cardiovascular diseases; S3) endocrinology and metabolism; S4) gut, liver, microbiota and lifestyle interventions; S5) gene, cell therapy, and oncology; S6) reproduction biology; S7) personalised and gender medicine; and, S8) ageing-associated disorders. On top of that, the event will feature keynote lectures from world-renowned scientists, providing our audience with unique insights and perspectives on their areas of expertise. The meeting will also host oral abstract presentations, e-poster sessions, multi-focus plenary sessions, pre-meeting courses for young researchers, a welcome ceremony, the Champions League, and multiple and diverse ESCI grants and attractive awards (visit our website).</p><p>The ESCI Annual Scientific Meeting aims to bring together outstanding and distinguished speakers from diverse disciplines to present and share their knowledge, outline the most recent advances in the scientific and clinical field, and address hot controversial topics.</p><p>We look forward to welcoming all worldwide delegates since the ASM serves as an incredible event to exchange ideas, network with your peers and foster collaboration opportunities. On top of that, young investigators will also have the chance to discuss, criticise, and learn while in contact with senior top scientists in different fields.</p><p>With its rich cultural heritage and cosmopolitan metropolis open to the sea and mountains, Barcelona provides an ideal backdrop for this intellectually stimulating event.</p><p>\n <b>Gemma Vilahur</b>\n </p><p>\n <i>Chair ESCI - Annual Scientific Meeting Barcelona 2024</i>\n </p><p>Dr. Esteller graduated in Medicine from the Universitat de Barcelona, where he also obtained his Ph.D. in molecular genetics. Dr. Esteller was a Postdoctoral Fellow and a Research Associate at Johns Hopkins where he studied DNA methylation and human cancer.</p><p>His work was decisive in establishing promoter hypermethylation of tumor suppressor genes as a common hallmark of cancer.</p><p>From October 2001 to September 2008 Manel Esteller was the Leader of the CNIO Cancer Epigenetics Laboratory. Since October 2008 until May 2019, Dr Esteller was the Director of the Cancer Epigenetics and Biology Program (PEBC) in Barcelona. He is currently the Director of the Josep Carreras Leukaemia Research Institute (IJC), Chairman of Genetics in the School of Medicine of the University of Barcelona, and an ICREA Research Professor.</p><p>His current research is devoted to the establishment of the epigenome maps in health and disease, and the development of new epigenetic drugs. Author of numerous and highly cited peer-reviewed manuscripts in biomedical sciences, he has received prestigious recognitions for his scientific achievements among them the World Health Summit Award, the Swiss Bridge Cancer Award and the EACR Cancer Researcher Award Lecture.</p><p>Mitchell D. Fiet MSc</p><p>Department of Pathology, Amsterdam University Medical Center</p><p>Mitchell Fiet (Den Haag, The Netherlands) studied Biomedical Sciences in Leiden and went abroad to Düsseldorf (Germany). During his studies he developed an interest in immunology and cellular responses, prompting him to start his PhD at the Cardiovascular Pathology department of the Amsterdam UMC. During the PhD tract he would determine the immunomodulatory properties of stem cells in myocardial infarction and have a look at various markers in heart diseases.</p><p>The PhD is currently in the final phase and scheduled to finish this year.</p><p>The Cardiovascular Pathology group focuses on different diseases and mechanisms, such as myocardial infarction and lymphocytic myocarditis (LM), but also burn wounds. Examples of markers of disease that Mitchell looked into are perivascular nerve fibres in myocardial infarction and the conserved protein clusterin in LM, both indicative of a manifesting disease: There is limited knowledge on whether the morphologically normal myocardium is affected in LM and clusterin indicates a form of stress in cardiomyocytes. Ongoing projects are investigating the interplay of myocarditis with various other diseases and the effects of infection on atherosclerotic plaques.</p><p>Dr Nurulamin Noor</p><p>Academic Clinical Lecturer in Gastroenterology</p><p>University of Cambridge and Cambridge University Hospitals</p><p><i>Dr. Nurulamin Noor is a Clinical Lecturer in Gastroenterology at the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust. He also holds a post as an Honorary Postdoctoral Researcher in Clinical Trial Methodology at the Medical Research Council Clinical Trials Unit at University College London. He has clinical and academic interests in clinical trials, with a specific interest in improving outcomes for patients with digestive diseases - and with a focus on innovative approaches to trial design, conduct and analysis</i>.</p><p>Giampaolo Morciano, PhD, FESC</p><p>Dept. of Medical Sciences</p><p>Section of Experimental Medicine</p><p>Paolo Pinton's Lab</p><p>c/o CUBO Via Fossato di Mortara 70, 44121 Ferrara</p><p>Dott. G. Morciano holds two degrees in Biological Sciences (BS) and Biomolecular and Cellular Sciences (MS); in 2016 he achieved the PhD in Biochemistry at the University of Ferrara, focusing the research on the role of ATP synthase and the mitochondrial calcium channels in disease. He currently does basic and translational research at the Dept. of Medical Sciences, Section of Experimental Medicine in the same University. Most of his research is aimed at investigating molecular mechanisms underlying the processes of mitochondria-dependent cell death and heart maladaptation, which are crucial for cardioprotection; a small part on neurodegeneration and cancer. From 2021 he holds the role of Principal Investigator at the Cardiovascular Institute of Ferrara Hospital, heading a translational research project funded by the Italian Ministry of Health. Also, he supervises the scientific guidelines of the Mitochondrial Physiopathology laboratory at the Maria Cecilia Hospital (GVM Care&amp;Research, Cotignola), a centre highly specialized in cardiac surgery. The scientific activity and the publications made opened new horizons to his career: he is an inventor of 3 patents concerning 3 different classes of cardioprotective molecules and he was awarded of the prestigious title FESC by the European Society of Cardiology having demonstrated the highest professional standards and commitment to reducing the burden of cardiovascular disease.</p><p>\n <b>\n <i>Talking Neurodiversity across Portugal</i>\n </b>\n </p><p>INSERM and University of Bordeaux</p><p>“Talk Neuro to Me” (Fala-me Neuro in Portuguese) is a science outreach and communication project that engages in informal education of neuroscience in Portuguese. It aims to inspire and empower people of all ages to use that knowledge in their everyday lives. With a team of 17 enthusiastic neuroscientists and science communicators, we organize multiple initiatives to promote fair and inclusive access to neuroscience through local in-person sessions (organization and participation of 24 events so far) and the dissemination of digital content (&gt;400 original publications). Our work has stimulated neuroscience literacy and abundant interaction — reaching more than 38,000 people (online) and 1,800 (in person) of different backgrounds and ages, including more than 900 children and adolescents — and has been transforming how neuroscience is perceived by Portuguese-speaking persons at both national and international levels in the past three years.</p><p>\n <b>\n <i>Mythabolism: a boardgame to demystify metabolis</i>\n </b>\n </p><p>\n <b>Sara Martins, PhD candidate</b>\n </p><p>Laboratory of Mitochondrial Biomedicine and Theranostics</p><p>Doctoral programme of Experimental Biology and Biomedicine</p><p>Center for Neuroscience and Cell Biology (CNC), University of Coimbra.</p><p>\"Mythabolism\" aims to increase scientific and health literacy regarding metabolism, through creation of a boardgame to demystify metabolism. This project features a multidisciplinar academic team working together with partner associations and their audiences, in order to develop a quality and attractive game-based learning tool.</p><p>\n <b>Champions 2023</b>\n </p><p>The yearly Champions League Universities taking place during the opening and welcome of the Annual Scientific Meeting where teams of different countries and universities/hospitals compete in the Champions League Universities.</p><p>Dr. Valentín Fuster, General Director of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and President of the “Mount Sinai Fuster Heart Hospital”</p><p>The cardiologist Valentín Fuster currently combines roles as General Director of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) in Madrid and President of the “Mount Sinai Fuster Heart Hospital” and Physician-in-Chief at Mount Sinai Medical Center in New York.</p><p>Dr. Fuster is a world-renowned figure whose vision for health promotion has defined the roadmap to defeating the unsustainable pandemic of cardiovascular disease.</p><p>The innumerable positions Dr. Fuster has held during his career include President of the American Heart Association, President of the World Heart Federation, member of the Institute of Medicine of the US National Academy of Sciences, member of the US National Heart, Lung and Blood Institute Advisory Council, and President of the American College of Cardiology Training Program.</p><p>After qualifying in medicine at the University of Barcelona, Valentín Fuster continued his studies in the USA. He was professor of Medicine and Cardiovascular Diseases at the Mayo Medical School, Minnesota and at the Medical School of Mount Sinai Hospital, New York, and from 1991 to 1994 he was full professor of Medicine at Harvard Medical School in Boston. In 1994 he was named Director of the Cardiovascular Institute at Mount Sinai, a post he has combined since 2012 with that of Physician-in-Chief.</p><p>Dr. Fuster has been named Doctor Honoris Causa by thirty-five universities, and his immense scientific contribution is reflected in an H factor of 218 (Google Scholar). His contributions to cardiovascular medicine have had an enormous impact on the treatment of patients with heart disease. His research into the origin of cardiovascular events, which has contributed to improved treatment of heart attack patients, was recognized in the award of the 1996 Prince of Asturias Award for Technical and Scientific Research. Among his many achievements, Dr. Fuster is the only cardiologist to have received the highest research awards from the four leading international cardiology organizations: the American Heart Association, the American College of Cardiology, the European Society of Cardiology, and the Interamerican Society of Cardiology.</p><p>In 2008, Dr Fuster received the the Kurt Polzer Prize from the European Academy of Science and Arts. In 2009 he was awarded the prestigious Arrigo Recordati international award for his scientific advances in cardiovascular imaging. In June 2011 he was awarded the Lefoulon-Delalande Foundation–Institut de France Grand Prix Scientifique, considered the most important in cardiology, for his translational research into atherothrombotic disease. His many other prizes include the American Heart Association Gold Heart Award, Lewis A. Conner Memorial, and James B. Eric Achievement Award; the American College of Cardiology Distinguished Teacher Award; the American and European Societies of Cardiology Gold Medal; and the highest award in Medicine from Erasmus University Rotterdam. In 2012, Dr. Fuster was named by the American College of Cardiology as one of the two Living Legends in Cardiovascular Medicine and was also awarded the Research Achievement Award, the highest award given by the American Heart Association.</p><p>Dr. Fuster has also received the Ron Haddock International Impact Award from the American Heart Association and the American Stroke Association in recognition of his global leadership. Further recognition in Spain came in the form of the Severo Ochoa Prize for Biomedical Research and the Mapfre Foundation Lifetime Achievement Award, in recognition of his work on the prevention and treatment of cardiovascular disease. According to the evaluation committee, Dr. Fuster's career stands as a model of the kind of research and innovation in which Spain needs to excel in order to compete in the global economy. In 2017 he received the Grand Cross of the Civil Order of Alfonso X the Wise. In 2020 the Royal Family of Thailand awarded Dr. Valentín Fuster the 29<sup>th</sup> annual Prince Mahidol Prize in Medicine. This prestigious award from the Prince Mahidol Foundation recognizes Dr. Fuster's international leadership over the past 40 years through his innovative contributions to cardiovascular medicine, both in the research field and in clinical care, and more recently his tireless championing of health promotion throughout the world. Recently, the Cardiovascular Research Foundation (CRF) awarded Dr. Fuster the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Career Achievement Award. Recently, the American College of Cardiology instituted the Valentin Fuster Award in Science and Innovation for the next 15 years.</p><p>“Adipose tissue exhaustion, rather than obesity per se, leads toward the progression of non-alcoholic fatty liver disease: searching for the signals involved in the cross- talk WAT-liver”</p><p>The project aims to decipher new biomarkers and/or novel targets to identify visceral white adipose tissue exhaustion. This is a critical step in the etiology of the disease characterized by metabolic dysfunction, low grade chronic inflammation, and tissue fibrosis. The time-course approach will consist of a chronic exposition of male and female C57Bl/6JOlaHsd mice to an hypercaloric diet and the determination of depot specific differences in mass, potential tapering phenomenon, and the progression of liver steatosis. Prevention of visceral adipose tissue exhaustion is a strategic therapeutic approach as an early and preventive treatment of obesity, with the aim to delay NAFLD progression and obesity-associated pathologies.</p><p>Jorge Luis Alvarez</p><p>University of Barcelona</p><p>\n <b>Nuno Mendonca</b>\n </p><p>\n <b>NOVA Medical School, University of Lisbon, Portugal</b>\n </p><p><b>Title:</b> Improving physical frailty in older adults: exploring the interaction between protein intake and physical activity</p><p><b>Topic:</b> Physical Frailty</p><p><b>Short paragraph:</b> Frailty is a clinical syndrome defined as an increased vulnerability or failure to return to homeostatic equilibrium after a stressor event that increases the risk of disability, dependency, care home admission, hospitalisation and death. Pre-frailty and frailty are estimated to be present in 42% and 11% of community-dwelling older adults respectively, and both increase with age. Expert groups have suggested that protein and physical activity have a synergistic protective effect on age-related loss of muscle strength and muscle mass, an important component of physical frailty. This combination would further sensitize muscle to insulin and the anabolic effects of aminoacids, optimally stimulating the rate of muscle protein synthesis. We aim to determine whether transitions between frailty states, especially frailty incidence vary by protein intake in older adults, and if there is a synergistic effect with physical activity.</p><p>\n <b>Aging in focus: A Comprehensive view for enhancing heathspan</b>\n </p><p>With great pleasure, we announce the 58th annual scientific meeting of the European Society for Clinical Investigation, which will be held in Genoa, Italy, on May 21-23, 2025.</p><p>In the wake on – and pushing on by – pandemic wave, the scientific community is experiencing new and exciting paradigm shifts. From the rapid evolution of artificial intelligence and cell/gene therapies to the growing interest in how environmental changes affect human health the timeless words of Karl Popper still resonate loudly.</p><p>Gaining awareness on aging as unavoidable process isn’t a defeat but rather a catalyst for contemporary scientific research. While the medical field takes the lead in this endeavor, it’s increasingly intertwined with ever-broader areas of science.</p><p>These are the principles we aim to imprint and upon which we work to build an exciting scientific program. We are planning several parallel symposia covering different aspects of aging in human health and disease. Keynote lectures, abstract presentations and pre-meeting courses will compose a consolidated recipe for a successful ESCI meeting.</p><p>Not by chance, Liguria, with Genoa as its capital, has been certified by the European Community as the oldest region in Europe. Long time aware of this – and a paradigm of the abovementioned concepts – the local government and healthcare system had to rethink the economic activities, environmental management, connectivity and housing to maintain resident well-being.</p><p>Why do people live longer in Liguria? We invite you to discover it! Amazing landscapes, where the mountains meet the sea face to face, a thousand-year history and a cuisine waiting to be discovered. These are some of our secrets that provide an ideal backdrop for three days of science, networking, and, why not, a bit of fun!</p><p>Saves the dates! We look forward to welcoming you to Genoa!</p><p>Federico Carbone</p><p>Luca Liberale</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":null,"pages":null},"PeriodicalIF":4.4000,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/eci.14236","citationCount":"0","resultStr":"{\"title\":\"ESCI Newsletter\",\"authors\":\"\",\"doi\":\"10.1111/eci.14236\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Welcome to Barcelona.</p><p>On behalf of the Organizing Committee, it is a pleasure to invite you to the</p><p><b>58th Annual Scientific Meeting</b> of the <b>European Society of Clinical Investigation</b>, which will be held in the lively city of <b>Barcelona</b>, Spain, <b>June 5-7, 2024</b></p><p>Both the whole Council of ESCI and the Local Organisers are committed to offering you a unique scientific event to stay at the forefront of the newest scientific discoveries, connect with peers, and contribute to the collective advancement of medical practice through science.</p><p>The <b>Congress Programme</b>, embraced under the theme <b>\\\"Connecting the Dots: The Power of Integrative Medicine</b>\\\", will feature eight different Symposiums running in parallel to provide a holistic and multidisciplinary overview of human health and disease. The symposium will cover: S1) the pathology and physiology of mitochondria; S2) cardiovascular diseases; S3) endocrinology and metabolism; S4) gut, liver, microbiota and lifestyle interventions; S5) gene, cell therapy, and oncology; S6) reproduction biology; S7) personalised and gender medicine; and, S8) ageing-associated disorders. On top of that, the event will feature keynote lectures from world-renowned scientists, providing our audience with unique insights and perspectives on their areas of expertise. The meeting will also host oral abstract presentations, e-poster sessions, multi-focus plenary sessions, pre-meeting courses for young researchers, a welcome ceremony, the Champions League, and multiple and diverse ESCI grants and attractive awards (visit our website).</p><p>The ESCI Annual Scientific Meeting aims to bring together outstanding and distinguished speakers from diverse disciplines to present and share their knowledge, outline the most recent advances in the scientific and clinical field, and address hot controversial topics.</p><p>We look forward to welcoming all worldwide delegates since the ASM serves as an incredible event to exchange ideas, network with your peers and foster collaboration opportunities. On top of that, young investigators will also have the chance to discuss, criticise, and learn while in contact with senior top scientists in different fields.</p><p>With its rich cultural heritage and cosmopolitan metropolis open to the sea and mountains, Barcelona provides an ideal backdrop for this intellectually stimulating event.</p><p>\\n <b>Gemma Vilahur</b>\\n </p><p>\\n <i>Chair ESCI - Annual Scientific Meeting Barcelona 2024</i>\\n </p><p>Dr. Esteller graduated in Medicine from the Universitat de Barcelona, where he also obtained his Ph.D. in molecular genetics. Dr. Esteller was a Postdoctoral Fellow and a Research Associate at Johns Hopkins where he studied DNA methylation and human cancer.</p><p>His work was decisive in establishing promoter hypermethylation of tumor suppressor genes as a common hallmark of cancer.</p><p>From October 2001 to September 2008 Manel Esteller was the Leader of the CNIO Cancer Epigenetics Laboratory. Since October 2008 until May 2019, Dr Esteller was the Director of the Cancer Epigenetics and Biology Program (PEBC) in Barcelona. He is currently the Director of the Josep Carreras Leukaemia Research Institute (IJC), Chairman of Genetics in the School of Medicine of the University of Barcelona, and an ICREA Research Professor.</p><p>His current research is devoted to the establishment of the epigenome maps in health and disease, and the development of new epigenetic drugs. Author of numerous and highly cited peer-reviewed manuscripts in biomedical sciences, he has received prestigious recognitions for his scientific achievements among them the World Health Summit Award, the Swiss Bridge Cancer Award and the EACR Cancer Researcher Award Lecture.</p><p>Mitchell D. Fiet MSc</p><p>Department of Pathology, Amsterdam University Medical Center</p><p>Mitchell Fiet (Den Haag, The Netherlands) studied Biomedical Sciences in Leiden and went abroad to Düsseldorf (Germany). During his studies he developed an interest in immunology and cellular responses, prompting him to start his PhD at the Cardiovascular Pathology department of the Amsterdam UMC. During the PhD tract he would determine the immunomodulatory properties of stem cells in myocardial infarction and have a look at various markers in heart diseases.</p><p>The PhD is currently in the final phase and scheduled to finish this year.</p><p>The Cardiovascular Pathology group focuses on different diseases and mechanisms, such as myocardial infarction and lymphocytic myocarditis (LM), but also burn wounds. Examples of markers of disease that Mitchell looked into are perivascular nerve fibres in myocardial infarction and the conserved protein clusterin in LM, both indicative of a manifesting disease: There is limited knowledge on whether the morphologically normal myocardium is affected in LM and clusterin indicates a form of stress in cardiomyocytes. Ongoing projects are investigating the interplay of myocarditis with various other diseases and the effects of infection on atherosclerotic plaques.</p><p>Dr Nurulamin Noor</p><p>Academic Clinical Lecturer in Gastroenterology</p><p>University of Cambridge and Cambridge University Hospitals</p><p><i>Dr. Nurulamin Noor is a Clinical Lecturer in Gastroenterology at the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust. He also holds a post as an Honorary Postdoctoral Researcher in Clinical Trial Methodology at the Medical Research Council Clinical Trials Unit at University College London. He has clinical and academic interests in clinical trials, with a specific interest in improving outcomes for patients with digestive diseases - and with a focus on innovative approaches to trial design, conduct and analysis</i>.</p><p>Giampaolo Morciano, PhD, FESC</p><p>Dept. of Medical Sciences</p><p>Section of Experimental Medicine</p><p>Paolo Pinton's Lab</p><p>c/o CUBO Via Fossato di Mortara 70, 44121 Ferrara</p><p>Dott. G. Morciano holds two degrees in Biological Sciences (BS) and Biomolecular and Cellular Sciences (MS); in 2016 he achieved the PhD in Biochemistry at the University of Ferrara, focusing the research on the role of ATP synthase and the mitochondrial calcium channels in disease. He currently does basic and translational research at the Dept. of Medical Sciences, Section of Experimental Medicine in the same University. Most of his research is aimed at investigating molecular mechanisms underlying the processes of mitochondria-dependent cell death and heart maladaptation, which are crucial for cardioprotection; a small part on neurodegeneration and cancer. From 2021 he holds the role of Principal Investigator at the Cardiovascular Institute of Ferrara Hospital, heading a translational research project funded by the Italian Ministry of Health. Also, he supervises the scientific guidelines of the Mitochondrial Physiopathology laboratory at the Maria Cecilia Hospital (GVM Care&amp;Research, Cotignola), a centre highly specialized in cardiac surgery. The scientific activity and the publications made opened new horizons to his career: he is an inventor of 3 patents concerning 3 different classes of cardioprotective molecules and he was awarded of the prestigious title FESC by the European Society of Cardiology having demonstrated the highest professional standards and commitment to reducing the burden of cardiovascular disease.</p><p>\\n <b>\\n <i>Talking Neurodiversity across Portugal</i>\\n </b>\\n </p><p>INSERM and University of Bordeaux</p><p>“Talk Neuro to Me” (Fala-me Neuro in Portuguese) is a science outreach and communication project that engages in informal education of neuroscience in Portuguese. It aims to inspire and empower people of all ages to use that knowledge in their everyday lives. With a team of 17 enthusiastic neuroscientists and science communicators, we organize multiple initiatives to promote fair and inclusive access to neuroscience through local in-person sessions (organization and participation of 24 events so far) and the dissemination of digital content (&gt;400 original publications). Our work has stimulated neuroscience literacy and abundant interaction — reaching more than 38,000 people (online) and 1,800 (in person) of different backgrounds and ages, including more than 900 children and adolescents — and has been transforming how neuroscience is perceived by Portuguese-speaking persons at both national and international levels in the past three years.</p><p>\\n <b>\\n <i>Mythabolism: a boardgame to demystify metabolis</i>\\n </b>\\n </p><p>\\n <b>Sara Martins, PhD candidate</b>\\n </p><p>Laboratory of Mitochondrial Biomedicine and Theranostics</p><p>Doctoral programme of Experimental Biology and Biomedicine</p><p>Center for Neuroscience and Cell Biology (CNC), University of Coimbra.</p><p>\\\"Mythabolism\\\" aims to increase scientific and health literacy regarding metabolism, through creation of a boardgame to demystify metabolism. This project features a multidisciplinar academic team working together with partner associations and their audiences, in order to develop a quality and attractive game-based learning tool.</p><p>\\n <b>Champions 2023</b>\\n </p><p>The yearly Champions League Universities taking place during the opening and welcome of the Annual Scientific Meeting where teams of different countries and universities/hospitals compete in the Champions League Universities.</p><p>Dr. Valentín Fuster, General Director of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and President of the “Mount Sinai Fuster Heart Hospital”</p><p>The cardiologist Valentín Fuster currently combines roles as General Director of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) in Madrid and President of the “Mount Sinai Fuster Heart Hospital” and Physician-in-Chief at Mount Sinai Medical Center in New York.</p><p>Dr. Fuster is a world-renowned figure whose vision for health promotion has defined the roadmap to defeating the unsustainable pandemic of cardiovascular disease.</p><p>The innumerable positions Dr. Fuster has held during his career include President of the American Heart Association, President of the World Heart Federation, member of the Institute of Medicine of the US National Academy of Sciences, member of the US National Heart, Lung and Blood Institute Advisory Council, and President of the American College of Cardiology Training Program.</p><p>After qualifying in medicine at the University of Barcelona, Valentín Fuster continued his studies in the USA. He was professor of Medicine and Cardiovascular Diseases at the Mayo Medical School, Minnesota and at the Medical School of Mount Sinai Hospital, New York, and from 1991 to 1994 he was full professor of Medicine at Harvard Medical School in Boston. In 1994 he was named Director of the Cardiovascular Institute at Mount Sinai, a post he has combined since 2012 with that of Physician-in-Chief.</p><p>Dr. Fuster has been named Doctor Honoris Causa by thirty-five universities, and his immense scientific contribution is reflected in an H factor of 218 (Google Scholar). His contributions to cardiovascular medicine have had an enormous impact on the treatment of patients with heart disease. His research into the origin of cardiovascular events, which has contributed to improved treatment of heart attack patients, was recognized in the award of the 1996 Prince of Asturias Award for Technical and Scientific Research. Among his many achievements, Dr. Fuster is the only cardiologist to have received the highest research awards from the four leading international cardiology organizations: the American Heart Association, the American College of Cardiology, the European Society of Cardiology, and the Interamerican Society of Cardiology.</p><p>In 2008, Dr Fuster received the the Kurt Polzer Prize from the European Academy of Science and Arts. In 2009 he was awarded the prestigious Arrigo Recordati international award for his scientific advances in cardiovascular imaging. In June 2011 he was awarded the Lefoulon-Delalande Foundation–Institut de France Grand Prix Scientifique, considered the most important in cardiology, for his translational research into atherothrombotic disease. His many other prizes include the American Heart Association Gold Heart Award, Lewis A. Conner Memorial, and James B. Eric Achievement Award; the American College of Cardiology Distinguished Teacher Award; the American and European Societies of Cardiology Gold Medal; and the highest award in Medicine from Erasmus University Rotterdam. In 2012, Dr. Fuster was named by the American College of Cardiology as one of the two Living Legends in Cardiovascular Medicine and was also awarded the Research Achievement Award, the highest award given by the American Heart Association.</p><p>Dr. Fuster has also received the Ron Haddock International Impact Award from the American Heart Association and the American Stroke Association in recognition of his global leadership. Further recognition in Spain came in the form of the Severo Ochoa Prize for Biomedical Research and the Mapfre Foundation Lifetime Achievement Award, in recognition of his work on the prevention and treatment of cardiovascular disease. According to the evaluation committee, Dr. Fuster's career stands as a model of the kind of research and innovation in which Spain needs to excel in order to compete in the global economy. In 2017 he received the Grand Cross of the Civil Order of Alfonso X the Wise. In 2020 the Royal Family of Thailand awarded Dr. Valentín Fuster the 29<sup>th</sup> annual Prince Mahidol Prize in Medicine. This prestigious award from the Prince Mahidol Foundation recognizes Dr. Fuster's international leadership over the past 40 years through his innovative contributions to cardiovascular medicine, both in the research field and in clinical care, and more recently his tireless championing of health promotion throughout the world. Recently, the Cardiovascular Research Foundation (CRF) awarded Dr. Fuster the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Career Achievement Award. Recently, the American College of Cardiology instituted the Valentin Fuster Award in Science and Innovation for the next 15 years.</p><p>“Adipose tissue exhaustion, rather than obesity per se, leads toward the progression of non-alcoholic fatty liver disease: searching for the signals involved in the cross- talk WAT-liver”</p><p>The project aims to decipher new biomarkers and/or novel targets to identify visceral white adipose tissue exhaustion. This is a critical step in the etiology of the disease characterized by metabolic dysfunction, low grade chronic inflammation, and tissue fibrosis. The time-course approach will consist of a chronic exposition of male and female C57Bl/6JOlaHsd mice to an hypercaloric diet and the determination of depot specific differences in mass, potential tapering phenomenon, and the progression of liver steatosis. Prevention of visceral adipose tissue exhaustion is a strategic therapeutic approach as an early and preventive treatment of obesity, with the aim to delay NAFLD progression and obesity-associated pathologies.</p><p>Jorge Luis Alvarez</p><p>University of Barcelona</p><p>\\n <b>Nuno Mendonca</b>\\n </p><p>\\n <b>NOVA Medical School, University of Lisbon, Portugal</b>\\n </p><p><b>Title:</b> Improving physical frailty in older adults: exploring the interaction between protein intake and physical activity</p><p><b>Topic:</b> Physical Frailty</p><p><b>Short paragraph:</b> Frailty is a clinical syndrome defined as an increased vulnerability or failure to return to homeostatic equilibrium after a stressor event that increases the risk of disability, dependency, care home admission, hospitalisation and death. Pre-frailty and frailty are estimated to be present in 42% and 11% of community-dwelling older adults respectively, and both increase with age. Expert groups have suggested that protein and physical activity have a synergistic protective effect on age-related loss of muscle strength and muscle mass, an important component of physical frailty. This combination would further sensitize muscle to insulin and the anabolic effects of aminoacids, optimally stimulating the rate of muscle protein synthesis. We aim to determine whether transitions between frailty states, especially frailty incidence vary by protein intake in older adults, and if there is a synergistic effect with physical activity.</p><p>\\n <b>Aging in focus: A Comprehensive view for enhancing heathspan</b>\\n </p><p>With great pleasure, we announce the 58th annual scientific meeting of the European Society for Clinical Investigation, which will be held in Genoa, Italy, on May 21-23, 2025.</p><p>In the wake on – and pushing on by – pandemic wave, the scientific community is experiencing new and exciting paradigm shifts. From the rapid evolution of artificial intelligence and cell/gene therapies to the growing interest in how environmental changes affect human health the timeless words of Karl Popper still resonate loudly.</p><p>Gaining awareness on aging as unavoidable process isn’t a defeat but rather a catalyst for contemporary scientific research. While the medical field takes the lead in this endeavor, it’s increasingly intertwined with ever-broader areas of science.</p><p>These are the principles we aim to imprint and upon which we work to build an exciting scientific program. We are planning several parallel symposia covering different aspects of aging in human health and disease. Keynote lectures, abstract presentations and pre-meeting courses will compose a consolidated recipe for a successful ESCI meeting.</p><p>Not by chance, Liguria, with Genoa as its capital, has been certified by the European Community as the oldest region in Europe. Long time aware of this – and a paradigm of the abovementioned concepts – the local government and healthcare system had to rethink the economic activities, environmental management, connectivity and housing to maintain resident well-being.</p><p>Why do people live longer in Liguria? We invite you to discover it! Amazing landscapes, where the mountains meet the sea face to face, a thousand-year history and a cuisine waiting to be discovered. These are some of our secrets that provide an ideal backdrop for three days of science, networking, and, why not, a bit of fun!</p><p>Saves the dates! We look forward to welcoming you to Genoa!</p><p>Federico Carbone</p><p>Luca Liberale</p>\",\"PeriodicalId\":12013,\"journal\":{\"name\":\"European Journal of Clinical Investigation\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2024-05-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/eci.14236\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Clinical Investigation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/eci.14236\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/eci.14236","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

欢迎来到巴塞罗那。我谨代表组委会荣幸地邀请您参加将于 2024 年 6 月 5 日至 7 日在西班牙巴塞罗那这座充满活力的城市举行的欧洲临床研究学会第 58 届科学年会。欧洲临床研究学会全体理事会和当地主办方都致力于为您提供一个独特的科学盛会,让您始终走在最新科学发现的前沿,与同行交流,并通过科学为医疗实践的集体进步做出贡献。大会日程以 "连接点:中西医结合的力量 "为主题,将同时举办八场不同的专题讨论会,以提供有关人类健康和疾病的整体和多学科概览。专题讨论会将涵盖S1)线粒体的病理学和生理学;S2)心血管疾病;S3)内分泌学和新陈代谢;S4)肠道、肝脏、微生物群和生活方式干预;S5)基因、细胞疗法和肿瘤学;S6)生殖生物学;S7)个性化和性别医学;S8)老龄相关疾病。此外,大会还将邀请世界知名科学家做主题演讲,为听众提供其专业领域的独特见解和观点。会议还将举办口头摘要报告、电子海报会议、多焦点全体会议、针对年轻研究人员的会前课程、欢迎仪式、冠军联赛以及多种多样的ESCI补助金和有吸引力的奖项(请访问我们的网站)。ESCI科学年会旨在汇聚来自不同学科的杰出演讲者,介绍和分享他们的知识,概述科学和临床领域的最新进展,并讨论有争议的热点话题。此外,年轻的研究人员还将有机会与不同领域的资深顶尖科学家进行讨论、批评和学习。巴塞罗那拥有丰富的文化遗产和依山傍海的国际化大都市,是举办这一智力盛会的理想背景。 Gemma Vilahur 主席 ESCI - 2024 年巴塞罗那科学年会 Esteller 博士毕业于巴塞罗那大学(Universitat de Barcelona)医学系,并在该校获得分子遗传学博士学位。2001 年 10 月至 2008 年 9 月,Manel Esteller 担任 CNIO 癌症表观遗传学实验室负责人。自2008年10月至2019年5月,Esteller博士担任巴塞罗那癌症表观遗传学和生物学项目(PEBC)主任。他目前的研究致力于建立健康和疾病中的表观基因组图谱,以及开发新的表观遗传药物。他撰写了大量经同行评审的生物医学手稿,引用率极高。他的科学成就获得了众多权威机构的认可,其中包括世界卫生峰会奖、瑞士桥癌症奖和欧洲癌症研究中心癌症研究员奖讲座。 Mitchell D. Fiet MSc阿姆斯特丹大学医学中心病理学系Mitchell Fiet(荷兰登哈格)曾在莱顿攻读生物医学科学,后前往德国杜塞尔多夫留学。在学习期间,他对免疫学和细胞反应产生了浓厚的兴趣,这促使他在阿姆斯特丹大学医学中心心血管病理系开始攻读博士学位。心血管病理小组主要研究不同的疾病和机制,如心肌梗塞和淋巴细胞性心肌炎(LM),以及烧伤。米切尔研究的疾病标志物包括心肌梗塞中的血管周围神经纤维和淋巴细胞性心肌炎中的保守蛋白簇蛋白,这两种标志物都表明疾病正在显现:人们对 LM 中形态正常的心肌是否受到影响所知有限,而集束蛋白则表明心肌细胞中存在某种形式的应激。正在进行的项目正在研究心肌炎与其他各种疾病的相互作用以及感染对动脉粥样硬化斑块的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

ESCI Newsletter

ESCI Newsletter

Welcome to Barcelona.

On behalf of the Organizing Committee, it is a pleasure to invite you to the

58th Annual Scientific Meeting of the European Society of Clinical Investigation, which will be held in the lively city of Barcelona, Spain, June 5-7, 2024

Both the whole Council of ESCI and the Local Organisers are committed to offering you a unique scientific event to stay at the forefront of the newest scientific discoveries, connect with peers, and contribute to the collective advancement of medical practice through science.

The Congress Programme, embraced under the theme "Connecting the Dots: The Power of Integrative Medicine", will feature eight different Symposiums running in parallel to provide a holistic and multidisciplinary overview of human health and disease. The symposium will cover: S1) the pathology and physiology of mitochondria; S2) cardiovascular diseases; S3) endocrinology and metabolism; S4) gut, liver, microbiota and lifestyle interventions; S5) gene, cell therapy, and oncology; S6) reproduction biology; S7) personalised and gender medicine; and, S8) ageing-associated disorders. On top of that, the event will feature keynote lectures from world-renowned scientists, providing our audience with unique insights and perspectives on their areas of expertise. The meeting will also host oral abstract presentations, e-poster sessions, multi-focus plenary sessions, pre-meeting courses for young researchers, a welcome ceremony, the Champions League, and multiple and diverse ESCI grants and attractive awards (visit our website).

The ESCI Annual Scientific Meeting aims to bring together outstanding and distinguished speakers from diverse disciplines to present and share their knowledge, outline the most recent advances in the scientific and clinical field, and address hot controversial topics.

We look forward to welcoming all worldwide delegates since the ASM serves as an incredible event to exchange ideas, network with your peers and foster collaboration opportunities. On top of that, young investigators will also have the chance to discuss, criticise, and learn while in contact with senior top scientists in different fields.

With its rich cultural heritage and cosmopolitan metropolis open to the sea and mountains, Barcelona provides an ideal backdrop for this intellectually stimulating event.

Gemma Vilahur

Chair ESCI - Annual Scientific Meeting Barcelona 2024

Dr. Esteller graduated in Medicine from the Universitat de Barcelona, where he also obtained his Ph.D. in molecular genetics. Dr. Esteller was a Postdoctoral Fellow and a Research Associate at Johns Hopkins where he studied DNA methylation and human cancer.

His work was decisive in establishing promoter hypermethylation of tumor suppressor genes as a common hallmark of cancer.

From October 2001 to September 2008 Manel Esteller was the Leader of the CNIO Cancer Epigenetics Laboratory. Since October 2008 until May 2019, Dr Esteller was the Director of the Cancer Epigenetics and Biology Program (PEBC) in Barcelona. He is currently the Director of the Josep Carreras Leukaemia Research Institute (IJC), Chairman of Genetics in the School of Medicine of the University of Barcelona, and an ICREA Research Professor.

His current research is devoted to the establishment of the epigenome maps in health and disease, and the development of new epigenetic drugs. Author of numerous and highly cited peer-reviewed manuscripts in biomedical sciences, he has received prestigious recognitions for his scientific achievements among them the World Health Summit Award, the Swiss Bridge Cancer Award and the EACR Cancer Researcher Award Lecture.

Mitchell D. Fiet MSc

Department of Pathology, Amsterdam University Medical Center

Mitchell Fiet (Den Haag, The Netherlands) studied Biomedical Sciences in Leiden and went abroad to Düsseldorf (Germany). During his studies he developed an interest in immunology and cellular responses, prompting him to start his PhD at the Cardiovascular Pathology department of the Amsterdam UMC. During the PhD tract he would determine the immunomodulatory properties of stem cells in myocardial infarction and have a look at various markers in heart diseases.

The PhD is currently in the final phase and scheduled to finish this year.

The Cardiovascular Pathology group focuses on different diseases and mechanisms, such as myocardial infarction and lymphocytic myocarditis (LM), but also burn wounds. Examples of markers of disease that Mitchell looked into are perivascular nerve fibres in myocardial infarction and the conserved protein clusterin in LM, both indicative of a manifesting disease: There is limited knowledge on whether the morphologically normal myocardium is affected in LM and clusterin indicates a form of stress in cardiomyocytes. Ongoing projects are investigating the interplay of myocarditis with various other diseases and the effects of infection on atherosclerotic plaques.

Dr Nurulamin Noor

Academic Clinical Lecturer in Gastroenterology

University of Cambridge and Cambridge University Hospitals

Dr. Nurulamin Noor is a Clinical Lecturer in Gastroenterology at the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust. He also holds a post as an Honorary Postdoctoral Researcher in Clinical Trial Methodology at the Medical Research Council Clinical Trials Unit at University College London. He has clinical and academic interests in clinical trials, with a specific interest in improving outcomes for patients with digestive diseases - and with a focus on innovative approaches to trial design, conduct and analysis.

Giampaolo Morciano, PhD, FESC

Dept. of Medical Sciences

Section of Experimental Medicine

Paolo Pinton's Lab

c/o CUBO Via Fossato di Mortara 70, 44121 Ferrara

Dott. G. Morciano holds two degrees in Biological Sciences (BS) and Biomolecular and Cellular Sciences (MS); in 2016 he achieved the PhD in Biochemistry at the University of Ferrara, focusing the research on the role of ATP synthase and the mitochondrial calcium channels in disease. He currently does basic and translational research at the Dept. of Medical Sciences, Section of Experimental Medicine in the same University. Most of his research is aimed at investigating molecular mechanisms underlying the processes of mitochondria-dependent cell death and heart maladaptation, which are crucial for cardioprotection; a small part on neurodegeneration and cancer. From 2021 he holds the role of Principal Investigator at the Cardiovascular Institute of Ferrara Hospital, heading a translational research project funded by the Italian Ministry of Health. Also, he supervises the scientific guidelines of the Mitochondrial Physiopathology laboratory at the Maria Cecilia Hospital (GVM Care&Research, Cotignola), a centre highly specialized in cardiac surgery. The scientific activity and the publications made opened new horizons to his career: he is an inventor of 3 patents concerning 3 different classes of cardioprotective molecules and he was awarded of the prestigious title FESC by the European Society of Cardiology having demonstrated the highest professional standards and commitment to reducing the burden of cardiovascular disease.

Talking Neurodiversity across Portugal

INSERM and University of Bordeaux

“Talk Neuro to Me” (Fala-me Neuro in Portuguese) is a science outreach and communication project that engages in informal education of neuroscience in Portuguese. It aims to inspire and empower people of all ages to use that knowledge in their everyday lives. With a team of 17 enthusiastic neuroscientists and science communicators, we organize multiple initiatives to promote fair and inclusive access to neuroscience through local in-person sessions (organization and participation of 24 events so far) and the dissemination of digital content (>400 original publications). Our work has stimulated neuroscience literacy and abundant interaction — reaching more than 38,000 people (online) and 1,800 (in person) of different backgrounds and ages, including more than 900 children and adolescents — and has been transforming how neuroscience is perceived by Portuguese-speaking persons at both national and international levels in the past three years.

Mythabolism: a boardgame to demystify metabolis

Sara Martins, PhD candidate

Laboratory of Mitochondrial Biomedicine and Theranostics

Doctoral programme of Experimental Biology and Biomedicine

Center for Neuroscience and Cell Biology (CNC), University of Coimbra.

"Mythabolism" aims to increase scientific and health literacy regarding metabolism, through creation of a boardgame to demystify metabolism. This project features a multidisciplinar academic team working together with partner associations and their audiences, in order to develop a quality and attractive game-based learning tool.

Champions 2023

The yearly Champions League Universities taking place during the opening and welcome of the Annual Scientific Meeting where teams of different countries and universities/hospitals compete in the Champions League Universities.

Dr. Valentín Fuster, General Director of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and President of the “Mount Sinai Fuster Heart Hospital”

The cardiologist Valentín Fuster currently combines roles as General Director of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) in Madrid and President of the “Mount Sinai Fuster Heart Hospital” and Physician-in-Chief at Mount Sinai Medical Center in New York.

Dr. Fuster is a world-renowned figure whose vision for health promotion has defined the roadmap to defeating the unsustainable pandemic of cardiovascular disease.

The innumerable positions Dr. Fuster has held during his career include President of the American Heart Association, President of the World Heart Federation, member of the Institute of Medicine of the US National Academy of Sciences, member of the US National Heart, Lung and Blood Institute Advisory Council, and President of the American College of Cardiology Training Program.

After qualifying in medicine at the University of Barcelona, Valentín Fuster continued his studies in the USA. He was professor of Medicine and Cardiovascular Diseases at the Mayo Medical School, Minnesota and at the Medical School of Mount Sinai Hospital, New York, and from 1991 to 1994 he was full professor of Medicine at Harvard Medical School in Boston. In 1994 he was named Director of the Cardiovascular Institute at Mount Sinai, a post he has combined since 2012 with that of Physician-in-Chief.

Dr. Fuster has been named Doctor Honoris Causa by thirty-five universities, and his immense scientific contribution is reflected in an H factor of 218 (Google Scholar). His contributions to cardiovascular medicine have had an enormous impact on the treatment of patients with heart disease. His research into the origin of cardiovascular events, which has contributed to improved treatment of heart attack patients, was recognized in the award of the 1996 Prince of Asturias Award for Technical and Scientific Research. Among his many achievements, Dr. Fuster is the only cardiologist to have received the highest research awards from the four leading international cardiology organizations: the American Heart Association, the American College of Cardiology, the European Society of Cardiology, and the Interamerican Society of Cardiology.

In 2008, Dr Fuster received the the Kurt Polzer Prize from the European Academy of Science and Arts. In 2009 he was awarded the prestigious Arrigo Recordati international award for his scientific advances in cardiovascular imaging. In June 2011 he was awarded the Lefoulon-Delalande Foundation–Institut de France Grand Prix Scientifique, considered the most important in cardiology, for his translational research into atherothrombotic disease. His many other prizes include the American Heart Association Gold Heart Award, Lewis A. Conner Memorial, and James B. Eric Achievement Award; the American College of Cardiology Distinguished Teacher Award; the American and European Societies of Cardiology Gold Medal; and the highest award in Medicine from Erasmus University Rotterdam. In 2012, Dr. Fuster was named by the American College of Cardiology as one of the two Living Legends in Cardiovascular Medicine and was also awarded the Research Achievement Award, the highest award given by the American Heart Association.

Dr. Fuster has also received the Ron Haddock International Impact Award from the American Heart Association and the American Stroke Association in recognition of his global leadership. Further recognition in Spain came in the form of the Severo Ochoa Prize for Biomedical Research and the Mapfre Foundation Lifetime Achievement Award, in recognition of his work on the prevention and treatment of cardiovascular disease. According to the evaluation committee, Dr. Fuster's career stands as a model of the kind of research and innovation in which Spain needs to excel in order to compete in the global economy. In 2017 he received the Grand Cross of the Civil Order of Alfonso X the Wise. In 2020 the Royal Family of Thailand awarded Dr. Valentín Fuster the 29th annual Prince Mahidol Prize in Medicine. This prestigious award from the Prince Mahidol Foundation recognizes Dr. Fuster's international leadership over the past 40 years through his innovative contributions to cardiovascular medicine, both in the research field and in clinical care, and more recently his tireless championing of health promotion throughout the world. Recently, the Cardiovascular Research Foundation (CRF) awarded Dr. Fuster the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Career Achievement Award. Recently, the American College of Cardiology instituted the Valentin Fuster Award in Science and Innovation for the next 15 years.

“Adipose tissue exhaustion, rather than obesity per se, leads toward the progression of non-alcoholic fatty liver disease: searching for the signals involved in the cross- talk WAT-liver”

The project aims to decipher new biomarkers and/or novel targets to identify visceral white adipose tissue exhaustion. This is a critical step in the etiology of the disease characterized by metabolic dysfunction, low grade chronic inflammation, and tissue fibrosis. The time-course approach will consist of a chronic exposition of male and female C57Bl/6JOlaHsd mice to an hypercaloric diet and the determination of depot specific differences in mass, potential tapering phenomenon, and the progression of liver steatosis. Prevention of visceral adipose tissue exhaustion is a strategic therapeutic approach as an early and preventive treatment of obesity, with the aim to delay NAFLD progression and obesity-associated pathologies.

Jorge Luis Alvarez

University of Barcelona

Nuno Mendonca

NOVA Medical School, University of Lisbon, Portugal

Title: Improving physical frailty in older adults: exploring the interaction between protein intake and physical activity

Topic: Physical Frailty

Short paragraph: Frailty is a clinical syndrome defined as an increased vulnerability or failure to return to homeostatic equilibrium after a stressor event that increases the risk of disability, dependency, care home admission, hospitalisation and death. Pre-frailty and frailty are estimated to be present in 42% and 11% of community-dwelling older adults respectively, and both increase with age. Expert groups have suggested that protein and physical activity have a synergistic protective effect on age-related loss of muscle strength and muscle mass, an important component of physical frailty. This combination would further sensitize muscle to insulin and the anabolic effects of aminoacids, optimally stimulating the rate of muscle protein synthesis. We aim to determine whether transitions between frailty states, especially frailty incidence vary by protein intake in older adults, and if there is a synergistic effect with physical activity.

Aging in focus: A Comprehensive view for enhancing heathspan

With great pleasure, we announce the 58th annual scientific meeting of the European Society for Clinical Investigation, which will be held in Genoa, Italy, on May 21-23, 2025.

In the wake on – and pushing on by – pandemic wave, the scientific community is experiencing new and exciting paradigm shifts. From the rapid evolution of artificial intelligence and cell/gene therapies to the growing interest in how environmental changes affect human health the timeless words of Karl Popper still resonate loudly.

Gaining awareness on aging as unavoidable process isn’t a defeat but rather a catalyst for contemporary scientific research. While the medical field takes the lead in this endeavor, it’s increasingly intertwined with ever-broader areas of science.

These are the principles we aim to imprint and upon which we work to build an exciting scientific program. We are planning several parallel symposia covering different aspects of aging in human health and disease. Keynote lectures, abstract presentations and pre-meeting courses will compose a consolidated recipe for a successful ESCI meeting.

Not by chance, Liguria, with Genoa as its capital, has been certified by the European Community as the oldest region in Europe. Long time aware of this – and a paradigm of the abovementioned concepts – the local government and healthcare system had to rethink the economic activities, environmental management, connectivity and housing to maintain resident well-being.

Why do people live longer in Liguria? We invite you to discover it! Amazing landscapes, where the mountains meet the sea face to face, a thousand-year history and a cuisine waiting to be discovered. These are some of our secrets that provide an ideal backdrop for three days of science, networking, and, why not, a bit of fun!

Saves the dates! We look forward to welcoming you to Genoa!

Federico Carbone

Luca Liberale

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
9.50
自引率
3.60%
发文量
192
审稿时长
1 months
期刊介绍: EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信